Yun Yen - Mar 31, 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Stock symbol
LIXT
Transactions as of
Mar 31, 2025
Transactions value $
$0
Form type
4
Date filed
4/2/2025, 10:36 AM
Previous filing
Jan 22, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +8.78K $0.00 8.78K Mar 31, 2025 Common 8.78K $1.21 Direct F1
holding LIXT Options to Purchase Common Stock 4.55K Mar 31, 2025 Common 4.55K $2.33 Direct
holding LIXT Options to Purchase Common Stock 5.79K Mar 31, 2025 Common 5.79K $1.30 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $2.37 Direct
holding LIXT Options to Purchase Common Stock 4.53K Mar 31, 2025 Common 4.53K $2.37 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K Mar 31, 2025 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 5.26K Mar 31, 2025 Common 5.26K $57.00 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 3.33K Mar 31, 2025 Common 3.33K $16.80 Direct
holding LIXT Options to Purchase Common Stock 833 Mar 31, 2025 Common 833 $66.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 8,777 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.